The international psychedelics market is on track for explosive growth, with new research estimating it will more than triple in value over the next decade. According to a recent report from Research and Markets, the industry — valued at $7.4 billion in 2025 — is expected to reach $22.6 billion by 2033, fueled by breakthroughs in mental health therapy and shifting public opinion.
The study examined both synthetic and naturally derived psychedelics currently being explored for medical and therapeutic purposes, including psilocybin, LSD, MDMA, ketamine, and DMT. Researchers noted growing evidence that these substances may provide effective treatment for conditions such as post-traumatic stress disorder (PTSD) and treatment-resistant depression, driving significant investment and interest in the field.
Distribution Channels Expanding
The report calculated the market based on products manufactured for medicinal, research, and recreational purposes, with primary distribution channels including online retailers, pharmacies, specialty stores, and dispensaries. Analysts highlighted the role of digital health platforms and new delivery formats as additional drivers of market expansion.
Regional Growth Hotspots
Europe and Latin America were identified as key growth regions, thanks to advancing policy reforms and stronger clinical infrastructure. The study also spotlighted major national markets, including the United States, Canada, Mexico, Germany, the United Kingdom, France, Spain, Italy, China, India, Japan, Australia, Brazil, and Argentina, with wider attention on the Middle East, Africa, and South and Central America.
U.S. Psychedelics Landscape
In the United States, policy shifts are already underway. Oregon and Colorado have legalized the therapeutic use of psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, marking the beginning of what could become broader state-level reform.
Public Opinion and Future Outlook
With a projected compound annual growth rate (CAGR) of 15%, the report attributes the market’s rapid expansion to a combination of growing scientific research and a notable shift in public opinion toward psychedelics’ potential benefits. The authors predict that as awareness spreads and more clinical studies validate therapeutic outcomes, the market will continue to attract investment, policy attention, and consumer demand.
If these projections hold, the psychedelic industry is set to become one of the fastest-growing global health and wellness sectors, transforming the way mental health is approached in the coming decade.
Your all-access pass to everything NECANN. Join our newsletter now
